Prosecution Insights
Last updated: April 19, 2026
Application No. 18/263,702

SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES

Non-Final OA §102
Filed
Jul 31, 2023
Examiner
HABTE, KAHSAY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Medshine Discovery Inc.
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
1y 11m
To Grant
93%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allow Rate
1348 granted / 1589 resolved
+24.8% vs TC avg
Moderate +8% lift
Without
With
+8.1%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
45 currently pending
Career history
1634
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
6.9%
-33.1% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
47.0%
+7.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1589 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-7 and 13-25 are pending in this application. Election/Restrictions Applicant’s election with traverse of Group I and a species b. (i.e. T = C, see compound of Example 8, paragraph [0393]) in the reply filed on 12/22/2025 is acknowledged. The traversal is on the ground that the restriction requirement between Groups I and II are without merit. Applicants argue that Groups I and II don’t lack unity of invention. The examiner disagrees with applicant’s argument. As set forth in the Restriction Requirement, Groups I and II lack unity of invention because the groups don not share the same or corresponding technical feature. Applicants also argue that the examination of Groups I and II should be examined together and would not require an additional burden of search. The examiner disagrees with applicant’s argument. The search for Group II would require search of subclasses unnecessary for the examination of the elected claims. For example, the search for the invention of Group II would include search of class A61K in EAST database and it also requires an additional text search in different databases. Therefore, co-examination of the additional invention would require a serious additional burden of search. The requirement is still deemed proper and is therefore made FINAL. Note that once the compounds of Group I are found allowable, the invention of Group II would be rejoined. The examiner searched the elected species and found no prior art. The search was expanded and stopped when a prior art was found. PNG media_image1.png 122 314 media_image1.png Greyscale Note that applicant’s invention is very broad and the examiner recommends that applicants review their invention. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 3-5 and 14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wermuth et al. U.S. Pat. No. 4,576,946. Cited reference teaches the following compounds that are the same as applicants when applicants formula (VI) has the following substituents: R1 = R2 = R5 = H; L = a bond; R6 = CH3; R7 = alkyl substituted by a heterocycle (i.e. Rd = morpholinyl). PNG media_image2.png 73 1005 media_image2.png Greyscale PNG media_image3.png 252 585 media_image3.png Greyscale PNG media_image4.png 385 1023 media_image4.png Greyscale Since said compounds are the same as applicants, a 102(a)(1) rejection is proper. Objection 5. Claims 2, 6-7, 13 and 15-22 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Allowable Subject Matter 6. Claims 23-24 are allowed. Information Disclosure Statement 7. Applicant’s Information Disclosure Statement, filed on 09/12/2025, 04/25/2025, 01/13/2025 and 01/19/2024 has been acknowledged. Please refer to Applicant’s copies of the 1449 submitted herewith. Conclusion 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte Ph.D. whose telephone number is (571)272-0667. The examiner can normally be reached on 8:30 - 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JEFFREY MURRAY can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Kahsay Habte/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jul 31, 2023
Application Filed
Jan 08, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590073
NOVEL PROCESS FOR THE PREPARATION OF MACROCYCLIC CHELANT 2,2',2''-(10-(2-HYDROXYPROPYL)-1,4,7,10-TETRA AZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND IT'S COMPLEXES WITH PARAMAGNETIC METAL IONS
2y 5m to grant Granted Mar 31, 2026
Patent 12590067
HERBICIDAL CYCLOHEXANEDIONE DERIVATIVES
2y 5m to grant Granted Mar 31, 2026
Patent 12583866
PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS
2y 5m to grant Granted Mar 24, 2026
Patent 12576040
IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Patent 12577253
5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
93%
With Interview (+8.1%)
1y 11m
Median Time to Grant
Low
PTA Risk
Based on 1589 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month